Known for his innovative work in blood cancer treatments, Professor Tam has played a key role in developing targeted therapies. He is the global lead investigator for the BTK inhibitor zanubrutinib, overseeing its development from the first patient dosed in Melbourne through international regulatory approvals. His groundbreaking study combining ibrutinib and venetoclax for chronic lymphocytic leukemia (CLL) was the first of its kind, with results published in the New England Journal of Medicine just five years after the trial began.
Before joining Alfred Health, Professor Tam led the Low-Grade Lymphoma and CLL program at the Peter MacCallum Cancer Center and Royal Melbourne Hospital for over a decade. In 2015, he led Australia’s participation in the pivotal trial for chimeric antigen receptor T-cell therapy in diffuse large B-cell lymphoma, helping secure public access to this life-saving treatment.
With over 240 peer-reviewed publications and more than 17,000 citations, Professor Tam’s research has significantly influenced modern lymphoma and CLL treatment.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.